Anna is an associate in Dorsey’s Trial group. She uses her unique background to make complex litigation matters manageable for her clients. She is equally comfortable with statistics-heavy analysis and text-driven interpretation. Before coming to Dorsey, Anna was an eighth-grade science teacher. From this experience, she gained valuable skills in simplifying challenging concepts and communicating effectively with a wide array of audiences.
Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under the False Claims Act (“FCA”). In a recent decision, Adventist Health System v. AbbVie, the Ninth Circuit reversed a district court to hold that a covered entity can pursue an FCA qui tam action premised on 340B overcharging even though Section 340B itself provides no private right...
The Department of Justice (DOJ) announced that False Claims Act (FCA) settlements and judgments surpassed $6.8 billion in FY 2025—the highest single-year total in FCA history.1 DOJ reported a record 1,297 qui tam filings and 401 new government investigations opened for the year. Healthcare fraud enforcement once again dominated the recoveries, accounting for more than $5.7 billion of the total. By the Numbers2 Total FCA recoveries:...
